Table 1.

Differences between patients with sporadic and familial PHEO. Univariate analysis.

Variable	Sporadic	Family	OR (95% CI)	p-Value
Female sex	32 (44.4%)	40 (55.6%)	1	0.019
Male sex	16 (25%)	48 (75%)	2.40 (1.15–4.99)
Age	50.39 ± 14.74 years	36.32 ± 12.39 years	0.93 (0.90–0.96)	<0.001
Bilaterality				<0.001
No	42 (60%)	28 (40%)	1
Yes	6 (9.1%)	60 (90.9%)	15.00 (5.71–39.41)
BP-related symptoms				<0.001
No	12 (16.4%)	61 (83.6%)	1
Yes	36 (57.1%)	27 (42.9%)	0.15 (0.07–0.33)
Cardiological symptoms				0.001
No	24 (25.8%)	69 (74.2%)	1
Yes	24 (55.8%)	19 (44.2%)	0.28 (0.13–0.59)
Neurological symptoms				0.012
No	27 (28.4%)	68 (71.6%)	1
Yes	21 (51.2%)	20 (48.8%)	0.38 (0.18–0.81)
Skin symptoms				0.009
No	30 (29.1%)	73 (70.9%)	1
Yes	18 (54.5%)	15 (45.5%)	0.34 (0.15–0.77)
Adrenergic profile				0.568
No	36 (35.6%)	65 (64.4%)	1
Yes	9 (30%)	21(70%)	1.29 (0.54–3.12)
Noradrenergic profile				0.915
No	38 (34.5%)	72 (65.5%)	1
Yes	7 (33.3%)	14 (66.7%)	1.06 (0.39–2.84)
Dopaminergic profile				0.644
No	44 (34.1%)	85 (65.9%)	1
Yes	1 (100%)	1 (50%)	0.52 (0.03–8.48)
Mixed profile				0.018
No	19 (25.7%)	55 (74.3%)	1
Yes	26 (45.6%)	31 (54.4%)	0.41 (0.20–0.86)
Normal profile				0.276
No	44 (35.5%)	80 (64.5%)	1
Yes	1 (14.3%)	6 (85.7%)	3.30 (0.39–28.29)
Mixed dopaminergic profile				0.42
No	17 (50%)	17 (50%)	1
Yes	9 (39.1%)	14 (60.9%)	1.56 (0.53–4.55)
PASS scale	3.95 ± 2.59	3.04 ± 2.17	0.85 (0.65–1.10)	0.213
Size	4.55 ± 3.24 cm	3.04 ± 1.89 cm	0.79 (0.67–0.92)	0.002